Targeting the lipids LPA and S1P and their signalling pathways to inhibit tumour progression.
about
Lysophosphatidic acid and apolipoprotein A1 predict increased risk of developing World Trade Center-lung injury: a nested case-control studyBiomarkers of World Trade Center particulate matter exposure: physiology of distal airway and blood biomarkers that predict FEV1 declineBiochemical and Structural Characterization of Lysophosphatidic Acid Binding by a Humanized Monoclonal AntibodyStructural Characterization of an LPA1 Second Extracellular Loop Mimetic with a Self-Assembling Coiled-Coil Folding ConstraintLysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis.Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid.Cytosolic phospholipase A2 and lysophospholipids in tumor angiogenesisExpression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases.ATX-LPA receptor axis in inflammation and cancer.Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma.Regulators of G-Protein signaling RGS10 and RGS17 regulate chemoresistance in ovarian cancer cells.Cancer treatment strategies targeting sphingolipid metabolism.Regulation of cancer cell migration and invasion by sphingosine-1-phosphateInduction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastomaAutotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer progressionSp-1 and c-Myc mediate lysophosphatidic acid-induced expression of vascular endothelial growth factor in ovarian cancer cells via a hypoxia-inducible factor-1-independent mechanism.Lysophospholipid interactions with protein targets.Sharpening the edges of understanding the structure/function of the LPA1 receptor: expression in cancer and mechanisms of regulation.Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR familyTargeting sphingosine kinase 1 inhibits Akt signaling, induces apoptosis, and suppresses growth of human glioblastoma cells and xenografts.Production and characterization of monoclonal anti-sphingosine-1-phosphate antibodies.Genome-wide DNA methylation profiles altered by Helicobacter pylori in gastric mucosa and blood leukocyte DNA.Regulation of the Hippo pathway and implications for anticancer drug development.Lysophospholipid receptor activation of RhoA and lipid signaling pathways.Lysophosphatidic acid induces both EGFR-dependent and EGFR-independent effects on DNA synthesis and migration in pancreatic and colorectal carcinoma cells.Tumor cell group via phospholipase A₂ is involved in prostate cancer development.Prevention of ocular scarring after glaucoma filtering surgery using the monoclonal antibody LT1009 (Sonepcizumab) in a rabbit model.Lysophosphatidic acid induces lymphangiogenesis and IL-8 production in vitro in human lymphatic endothelial cells.Lysophosphatidic acid receptor agonists and antagonists (WO2010051053).Differential expression of sphingosine-1-phosphate receptors 1-5 in the developing nervous system.Molecular Approaches To Target GPCRs in Cancer Therapy.
P2860
Q23915586-9A652845-EE43-4820-B14F-0E34A552A7E2Q23918414-A57E7A22-5B63-4ED3-9AE0-B2934CA54746Q27667249-F0AEEBB1-603A-4753-9241-3CF409A9C9ADQ27676584-659D1AF8-D415-458B-81FE-AE9D340CA557Q30489645-03B35E01-7C8E-419B-AF20-E0C5615CE9B6Q33955207-59317645-2FAE-4B8B-B842-C9CA2AC86896Q34145860-3B1FBC9D-25C9-4BE9-B6B7-C61DCA3D98FFQ34148745-38AC1579-1CAC-43A9-92E6-B9D790DF9599Q34199719-905E4A12-73A2-496C-B0A7-7BFFEC3CF6F1Q34314916-4E2FB5D5-9D72-44C0-B440-2BDD91482A63Q34335443-82D67184-8E43-40A1-A5C8-9706CFEFAC2FQ34790629-DA90D0E3-DE79-40D5-9045-A29D191D7210Q34878519-01E54DBE-F9C4-4F0A-980B-4EA44EE1D50EQ35845241-CD06F997-AF73-482E-A025-9F1C2C81EE39Q36399256-7F2CD4F0-9150-4055-965B-F606980311C9Q36915708-EA2044EA-3417-43C5-A0DE-E7F7B2C3D17DQ36930850-ABDA7058-B0CC-4B3D-98BA-22A7588740D8Q36932111-646AB4AA-83C0-4F2D-B68A-0720399999F6Q37316604-8E2CA52C-320E-4006-8670-9AAE9163D3CBQ37364840-0359A087-496E-4E6F-9068-AF3F8582ADDEQ37382152-D49A9802-618F-4E4B-815D-5AD5973324FBQ37392926-B153EC1A-A1A6-42AF-B5E7-69D1621F3599Q37593084-379DD349-B529-4528-AA22-1D66B8EA555DQ38044174-8C733F33-FD07-4EA6-A9E6-1286154F4899Q38834081-A6D61C7D-ACCD-4F9D-93A7-A7069A28E606Q39660426-2CEA5D3C-9DCD-4947-9803-0A63CF86CB16Q40418834-A3087EE8-94F0-4A41-9DC9-F32B8DBF529DQ41858308-93BBFFCF-F9BC-4B31-A8A4-8788E93CB1AAQ42021207-D2536A02-81EB-4CBE-ADA9-93C5245ED981Q46152441-5F8CF810-B18B-40F7-8C43-93424C6F3114Q46850333-8B3F6679-357A-4946-9C34-EDE88759BFB8
P2860
Targeting the lipids LPA and S1P and their signalling pathways to inhibit tumour progression.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Targeting the lipids LPA and S ...... to inhibit tumour progression.
@en
type
label
Targeting the lipids LPA and S ...... to inhibit tumour progression.
@en
prefLabel
Targeting the lipids LPA and S ...... to inhibit tumour progression.
@en
P2860
P1476
Targeting the lipids LPA and S ...... to inhibit tumour progression.
@en
P2093
Gordon B Mills
Mandi Murph
P2860
P356
10.1017/S1462399407000476
P577
2007-10-15T00:00:00Z